Advertisement
UK markets open in 58 minutes
  • NIKKEI 225

    37,638.12
    -821.96 (-2.14%)
     
  • HANG SENG

    17,248.78
    +47.51 (+0.28%)
     
  • CRUDE OIL

    82.96
    +0.15 (+0.18%)
     
  • GOLD FUTURES

    2,331.70
    -6.70 (-0.29%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • Bitcoin GBP

    51,474.15
    -2,025.46 (-3.79%)
     
  • CMC Crypto 200

    1,390.87
    +8.30 (+0.60%)
     
  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     
  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     

How Incyte’s Jakafi Performed in Q1 2018

How Incyte’s Jakafi Performed in Q1 2018

Incyte’s (INCY) oncology drug Jakafi (ruxolitinib) is approved for the treatment of myelofibrosis and polycythemia vera, two rare types of blood cancer.